Searching News Database: transdermal testosterone gel
HSMN NewsFeed - 4 Oct 2012
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
HSMN NewsFeed - 8 Dec 2011
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
HSMN NewsFeed - 4 Aug 2011
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
Antares Pharma Announces Positive Study Results with VIBEX(TM) MTX in Rheumatoid Arthritis Patients
HSMN NewsFeed - 11 Jul 2011
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
Watson and Antares Announce Exclusive License Agreement for Antares' Oxybutynin Gel Product (Anturol(R))
HSMN NewsFeed - 14 Feb 2011
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program
HSMN NewsFeed - 9 Feb 2010
BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
HSMN NewsFeed - 30 Jun 2009
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
HSMN NewsFeed - 15 Apr 2008
BioSante Pharmaceuticals Appoints Michael C. Snabes, M.D., PhD, Vice President, Clinical Development
BioSante Pharmaceuticals Appoints Michael C. Snabes, M.D., PhD, Vice President, Clinical Development
HSMN NewsFeed - 29 Jan 2008
BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for LibiGel(R) in FSD
BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for LibiGel(R) in FSD
HSMN NewsFeed - 5 Sep 2007
BioSante Pharmaceuticals Names Joy A. Thomas Vice President of Corporate Development
BioSante Pharmaceuticals Names Joy A. Thomas Vice President of Corporate Development
HSMN NewsFeed - 12 Jun 2007
BioSante Pharmaceuticals Announces Reinitiation of Product Development With Teva
BioSante Pharmaceuticals Announces Reinitiation of Product Development With Teva
HSMN NewsFeed - 7 May 2007
BioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei Bioscience
BioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei Bioscience
HSMN NewsFeed - 8 Nov 2006
BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
HSMN NewsFeed - 12 Oct 2006
BioSante Pharmaceuticals Presents Bio-E-Gel(R) Woman-to-Partner Transfer Study at Menopause Society Meeting
BioSante Pharmaceuticals Presents Bio-E-Gel(R) Woman-to-Partner Transfer Study at Menopause Society Meeting
Additional items found! 24
Members Archive contains
24 additional stories matching:
transdermal testosterone gel
(Password required)
transdermal testosterone gel
(Password required)